FDA has approved Tukysa (tucatinib) in combination with chemotherapy for the treatment of adults with advanced forms of HER2-positive breast cancer that can’t be removed with surgery, or has spread to other parts of the body, and who have received one or more prior treatments.
Read more: FDA Approves First New Drug Under International Collaboration, A Treatment Option for Patients with HER2-Positive Metastatic Breast Cancer